Jeffrey Bluestone, PhD

A.W. and Mary Margaret Clausen Distinguished Professor 

Director, Hormone Research Institute
Diabetes Center

Jeffrey Bluestone, PhD, is the A.W. and Mary Margaret Clausen Distinguished Professor of Metabolism and Endocrinology and is the Director of the Hormone Research Institute in the Diabetes Center. His research over the past 25 years has focused on understanding the basic processes that control T cell activation and immune tolerance in autoimmunity and organ transplantation. He and members of his lab have developed soluble receptor antagonists; monoclonal antibodies and animals deficient in individual members of TCR and co-stimulatory pathways to define their individual roles in transplant rejection and autoimmunity including a special emphasis on a specialized subset of T cells termed “regulatory T cells” (Treg). Tregs control fundamental aspect of immune homeostasis. During the last several years, his research has adapted the animal studies using biologics and cell based therapies to develop therapeutics that can be used in humans with autoimmunity and under conditions of allotransplant rejection. Moreover, a strong role for antigen-specific Tregs have been found in these model systems and further evidence in humanized mice and transplant patients that alloantigen-specific Tregs are more effective. Thus, the major goal of this work is to identify the antigen-specificity of thymic- and peripherally-derived Tregs with the expectation that these TCRs can be adapted for immunotherapy. Finally, his lab initiated several projects to determine mechanisms that control Treg stability. The goal is to develop approaches using pharmacogenomics to either stabilize or destabilize Tregs in autoimmunity and cancer.

In March 2010 Dr. Bluestone was appointed executive vice chancellor and provost at the University of California San Francisco (UCSF) serving as chief academic officer guiding the research and academic enterprise advancing the campus priorities in close collaboration with the chancellor and the campus leadership teams, and to oversee the campus ethics and compliance enterprise. Previously he served in a number of posts including Director of theUCSF Diabetes Center, as Director of the Immune Tolerance Network.

In June 2008 Dr. Bluestone served as interim vice chancellor of research; directing the advancement of cross-campus research initiatives, such as enhancing core research facilities. In this capacity, he played a leading role in coordinating and integrating current research cores. He worked also to strengthen external research partnerships, particularly with industry, and focused on facilitating the translation of UCSF discoveries into public benefit.

In 2009, Dr. Bluestone led the UCSF committee to strategize and secure funds available through the American Recovery and Reinvestment Act, making the campus one of the top institutional recipients in the nation of science-based stimulus funds.

Dr. Bluestone joined the UCSF faculty in 2000. He is an international leader in the field of immunotherapy, with a stellar record of scholarly achievement and a decade of significant contributions to the research enterprise at UCSF, including the creation and directorship of an integrated UCSF Diabetes Center to focus on translating basic research in both type 1 and type 2 diabetes into improved therapies for patients. He also founded and directed the Immune Tolerance Network, a consortium of more than 1,000 of the world’s leading scientific researchers and clinical specialists from nearly 50 institutions, with the mission of testing new therapies to promote immune tolerance in transplantation, autoimmune diseases, asthma and allergic diseases.

As a research scientist, Dr. Bluestone has helped clarify the body’s immune response on a molecular level. His systematic investigation has catalyzed recent progress in stem cell research, islet cell transplantation and immune tolerance therapies – experimentation that has formidably translated into drugs to treat human disease.

Through his 30-year scientific career, he has authored more than 300 peer-reviewed publications that include prominent papers in Nature, Nature Immunology, and the Journal of Immunology and Diabetes. He has received numerous accolades for his work, including his 2006 election to the American Academy of Arts and Sciences, the Mary Tyler Moore & Robert Levine Excellence in Clinical Research Award from the Juvenile Diabetes Research Foundation, and the distinguished alumni award from the Cornell Graduate School of Medical Science.

Prior to joining UCSF, Bluestone was at the University of Chicago, where he was a member of the Ben May Institute for Cancer Research, rising over 13 years from an associate professor to the director of the institute. He had previously worked for seven years in various roles at the National Cancer Institute of the National Institutes of Health, ultimately becoming a senior investigator in the Immunology Branch of the National Cancer Institute.

Dr. Bluestone earned both his BS in biology and his MS in microbiology from Rutgers State University, and his PhD in immunology from the Cornell Graduate School of Medical Science (Sloan-Kettering Division).

Publications: 

Regulatory T cell therapy for autoimmune and autoinflammatory diseases: the next frontier.

The Journal of allergy and clinical immunology

Esensten JH, Muller YD, Bluestone JA, Tang Q

Treg cells-the next frontier of cell therapy.

Science (New York, N.Y.)

Bluestone JA, Tang Q

Adoptive Regulatory T Cell Therapy in a Patient with Systemic Lupus Erythematosus.

Arthritis & rheumatology (Hoboken, N.J.)

Dall'Era M, Pauli ML, Remedios K, Taravati K, Sandoval PM, Putnam AL, Lares A, Haemel A, Tang Q, Hellerstein M, Fitch M, McNamara J, Welch B, Bluestone JA, Wofsy D, Rosenblum MD

Engineering a Single-Agent Cytokine/Antibody Fusion That Selectively Expands Regulatory T Cells for Autoimmune Disease Therapy.

Journal of immunology (Baltimore, Md. : 1950)

Spangler JB, Trotta E, Tomala J, Peck A, Young TA, Savvides CS, Silveria S, Votavova P, Salafsky J, Pande VS, Kovar M, Bluestone JA, Garcia KC

Chance favours the prepared mind.

Nature reviews. Immunology

Bluestone JA

Revisiting IL-2: Biology and therapeutic prospects.

Science immunology

Abbas AK, Trotta E, R Simeonov D, Marson A, Bluestone JA

A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism.

Nature medicine

Trotta E, Bessette PH, Silveria SL, Ely LK, Jude KM, Le DT, Holst CR, Coyle A, Potempa M, Lanier LL, Garcia KC, Crellin NK, Rondon IJ, Bluestone JA

Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors.

Diabetes

Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A, Rushakoff R, Lee J, Bluestone JA, Anderson M, Herold KC

Author Correction: Discovery of stimulation-responsive immune enhancers with CRISPR activation.

Nature

Simeonov DR, Gowen BG, Boontanrart M, Roth TL, Gagnon JD, Mumbach MR, Satpathy AT, Lee Y, Bray NL, Chan AY, Lituiev DS, Nguyen ML, Gate RE, Subramaniam M, Li Z, Woo JM, Mitros T, Ray GJ, Curie GL, Naddaf N, Chu JS, Ma H, Boyer E, Van Gool F, Huang H, Liu R, Tobin VR, Schumann K, Daly MJ, Farh KK, Ansel KM, Ye CJ, Greenleaf WJ, Anderson MS, Bluestone JA, Chang HY, Corn JE, Marson A

Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity.

Cell reports

Wang D, Quiros J, Mahuron K, Pai CC, Ranzani V, Young A, Silveria S, Harwin T, Abnousian A, Pagani M, Rosenblum MD, Van Gool F, Fong L, Bluestone JA, DuPage M

Stem Cell Therapies for Treating Diabetes: Progress and Remaining Challenges.

Cell stem cell

Sneddon JB, Tang Q, Stock P, Bluestone JA, Roy S, Desai T, Hebrok M

Pathological conversion of regulatory T cells is associated with loss of allotolerance.

Scientific reports

Hua J, Inomata T, Chen Y, Foulsham W, Stevenson W, Shiang T, Bluestone JA, Dana R

Revealing the specificity of regulatory T cells in murine autoimmune diabetes.

Proceedings of the National Academy of Sciences of the United States of America

Spence A, Purtha W, Tam J, Dong S, Kim Y, Ju CH, Sterling T, Nakayama M, Robinson WH, Bluestone JA, Anderson MS, Tang Q

Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes.

Science (New York, N.Y.)

Sockolosky JT, Trotta E, Parisi G, Picton L, Su LL, Le AC, Chhabra A, Silveria SL, George BM, King IC, Tiffany MR, Jude K, Sibener LV, Baker D, Shizuru JA, Ribas A, Bluestone JA, Garcia KC

Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization.

Frontiers in immunology

Fuchs A, Gliwinski M, Grageda N, Spiering R, Abbas AK, Appel S, Bacchetta R, Battaglia M, Berglund D, Blazar B, Bluestone JA, Bornhäuser M, Ten Brinke A, Brusko TM, Cools N, Cuturi MC, Geissler E, Giannoukakis N, Golab K, Hafler DA, van Ham SM, Hester J, Hippen K, Di Ianni M, Ilic N, Isaacs J, Issa F, Iwaszkiewicz-Grzes D, Jaeckel E, Joosten I, Klatzmann D, Koenen H, van Kooten C, Korsgren O, Kretschmer K, Levings M, Marek-Trzonkowska NM, Martinez-Llordella M, Miljkovic D, Mills KHG, Miranda JP, Piccirillo CA, Putnam AL, Ritter T, Roncarolo MG, Sakaguchi S, Sánchez-Ramón S, Sawitzki B, Sofronic-Milosavljevic L, Sykes M, Tang Q, Vives-Pi M, Waldmann H, Witkowski P, Wood KJ, Gregori S, Hilkens CMU, Lombardi G, Lord P, Martinez-Caceres EM, Trzonkowski P

Future cancer research priorities in the USA: a Lancet Oncology Commission.

The Lancet. Oncology

Jaffee EM, Dang CV, Agus DB, Alexander BM, Anderson KC, Ashworth A, Barker AD, Bastani R, Bhatia S, Bluestone JA, Brawley O, Butte AJ, Coit DG, Davidson NE, Davis M, DePinho RA, Diasio RB, Draetta G, Frazier AL, Futreal A, Gambhir SS, Ganz PA, Garraway L, Gerson S, Gupta S, Heath J, Hoffman RI, Hudis C, Hughes-Halbert C, Ibrahim R, Jadvar H, Kavanagh B, Kittles R, Le QT, Lippman SM, Mankoff D, Mardis ER, Mayer DK, McMasters K, Meropol NJ, Mitchell B, Naredi P, Ornish D, Pawlik TM, Peppercorn J, Pomper MG, Raghavan D, Ritchie C, Schwarz SW, Sullivan R, Wahl R, Wolchok JD, Wong SL, Yung A

Avidity and Bystander Suppressive Capacity of Human Regulatory T Cells Expressing De Novo Autoreactive T-Cell Receptors in Type 1 Diabetes.

Frontiers in immunology

Yeh WI, Seay HR, Newby B, Posgai AL, Moniz FB, Michels A, Mathews CE, Bluestone JA, Brusko TM

Discovery of stimulation-responsive immune enhancers with CRISPR activation.

Nature

Simeonov DR, Gowen BG, Boontanrart M, Roth TL, Gagnon JD, Mumbach MR, Satpathy AT, Lee Y, Bray NL, Chan AY, Lituiev DS, Nguyen ML, Gate RE, Subramaniam M, Li Z, Woo JM, Mitros T, Ray GJ, Curie GL, Naddaf N, Chu JS, Ma H, Boyer E, Van Gool F, Huang H, Liu R, Tobin VR, Schumann K, Daly MJ, Farh KK, Ansel KM, Ye CJ, Greenleaf WJ, Anderson MS, Bluestone JA, Chang HY, Corn JE, Marson A

Corrigendum: Is autoimmunity the Achilles' heel of cancer immunotherapy?

Nature medicine

June CH, Warshauer JT, Bluestone JA

Is autoimmunity the Achilles' heel of cancer immunotherapy?

Nature medicine

June CH, Warshauer JT, Bluestone JA

Targeting ABL-IRE1a Signaling Spares ER-Stressed Pancreatic ß Cells to Reverse Autoimmune Diabetes.

Cell metabolism

Morita S, Villalta SA, Feldman HC, Register AC, Rosenthal W, Hoffmann-Petersen IT, Mehdizadeh M, Ghosh R, Wang L, Colon-Negron K, Meza-Acevedo R, Backes BJ, Maly DJ, Bluestone JA, Papa FR

Targeting ABL-IRE1a Signaling Spares ER-Stressed Pancreatic ß Cells to Reverse Autoimmune Diabetes.

Cell metabolism

Morita S, Villalta SA, Feldman HC, Register AC, Rosenthal W, Hoffmann-Petersen IT, Mehdizadeh M, Ghosh R, Wang L, Colon-Negron K, Meza-Acevedo R, Backes BJ, Maly DJ, Bluestone JA, Papa FR

FOXP3, the Transcription Factor at the Heart of the Rebirth of Immune Tolerance.

Journal of immunology (Baltimore, Md. : 1950)

Bluestone JA

Expansion of Human Tregs from Cryopreserved Umbilical Cord Blood for GMP-Compliant Autologous Adoptive Cell Transfer Therapy.

Molecular therapy. Methods & clinical development

Seay HR, Putnam AL, Cserny J, Posgai AL, Rosenau EH, Wingard JR, Girard KF, Kraus M, Lares AP, Brown HL, Brown KS, Balavage KT, Peters LD, Bushdorf AN, Atkinson MA, Bluestone JA, Haller MJ, Brusko TM

Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials.

Annual review of pathology

Esensten JH, Bluestone JA, Lim WA

CD28 Costimulation: From Mechanism to Therapy.

Immunity

Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA

Correction: CD4+ Group 1 Innate Lymphoid Cells (ILC) Form a Functionally Distinct ILC Subset That Is Increased in Systemic Sclerosis.

Journal of immunology (Baltimore, Md. : 1950)

Roan F, Stoklasek TA, Whalen E, Molitor JA, Bluestone JA, Buckner JH, Ziegler SF

Regulatory T cell therapy for type 1 diabetes: May the force be with you.

Journal of autoimmunity

Gitelman SE, Bluestone JA

Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial.

Diabetologia

Gitelman SE, Gottlieb PA, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Harris KM, Kanaparthi S, Phippard D, Ding L, Bluestone JA, Ehlers MR

CD4+ Group 1 Innate Lymphoid Cells (ILC) Form a Functionally Distinct ILC Subset That Is Increased in Systemic Sclerosis.

Journal of immunology (Baltimore, Md. : 1950)

Roan F, Stoklasek TA, Whalen E, Molitor JA, Bluestone JA, Buckner JH, Ziegler SF

Inducing and Administering Tregs to Treat Human Disease.

Frontiers in immunology

Perdigoto AL, Chatenoud L, Bluestone JA, Herold KC

Type 1 diabetes immunotherapy using polyclonal regulatory T cells.

Science translational medicine

Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, Herold KC, Lares A, Lee MR, Li K, Liu W, Long SA, Masiello LM, Nguyen V, Putnam AL, Rieck M, Sayre PH, Tang Q

Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction.

Molecular genetics and metabolism

Kishnani PS, Dickson PI, Muldowney L, Lee JJ, Rosenberg A, Abichandani R, Bluestone JA, Burton BK, Dewey M, Freitas A, Gavin D, Griebel D, Hogan M, Holland S, Tanpaiboon P, Turka LA, Utz JJ, Wang YM, Whitley CB, Kazi ZB, Pariser AR

Shifting the Evolving CAR T Cell Platform into Higher Gear.

Cancer cell

Holohan DR, Lee JC, Bluestone JA

Targeting Treg signaling for the treatment of autoimmune diseases.

Current opinion in immunology

Spence A, Klementowicz JE, Bluestone JA, Tang Q

Generation of knock-in primary human T cells using Cas9 ribonucleoproteins.

Proceedings of the National Academy of Sciences of the United States of America

Schumann K, Lin S, Boyer E, Simeonov DR, Subramaniam M, Gate RE, Haliburton GE, Ye CJ, Bluestone JA, Doudna JA, Marson A

Interleukin-33 and Interferon-? Counter-Regulate Group 2 Innate Lymphoid Cell Activation during Immune Perturbation.

Immunity

Molofsky AB, Van Gool F, Liang HE, Van Dyken SJ, Nussbaum JC, Lee J, Bluestone JA, Locksley RM

Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226.

Journal of immunology (Baltimore, Md. : 1950)

Fuhrman CA, Yeh WI, Seay HR, Saikumar Lakshmi P, Chopra G, Zhang L, Perry DJ, McClymont SA, Yadav M, Lopez MC, Baker HV, Zhang Y, Li Y, Whitley M, von Schack D, Atkinson MA, Bluestone JA, Brusko TM

IL-2: Change Structure … Change Function.

Immunity

Bluestone JA, Crellin N, Trotta E

T cells in the control of organ-specific autoimmunity.

The Journal of clinical investigation

Bluestone JA, Bour-Jordan H, Cheng M, Anderson M

The therapeutic potential of regulatory T cells for the treatment of autoimmune disease.

Expert opinion on therapeutic targets

Bluestone JA, Trotta E, Xu D

Immunotherapy: making the case for precision medicine.

Science translational medicine

Bluestone JA, Tang Q

The immune system in Duchenne muscular dystrophy: Friend or foe.

Rare diseases (Austin, Tex.)

Villalta SA, Rosenberg AS, Bluestone JA

The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation.

Immunity

DuPage M, Chopra G, Quiros J, Rosenthal WL, Morar MM, Holohan D, Zhang R, Turka L, Marson A, Bluestone JA

Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability.

Nature immunology

Huynh A, DuPage M, Priyadharshini B, Sage PT, Quiros J, Borges CM, Townamchai N, Gerriets VA, Rathmell JC, Sharpe AH, Bluestone JA, Turka LA

Innate antiviral host defense attenuates TGF-ß function through IRF3-mediated suppression of Smad signaling.

Molecular cell

Xu P, Bailey-Bucktrout S, Xi Y, Xu D, Du D, Zhang Q, Xiang W, Liu J, Melton A, Sheppard D, Chapman HA, Bluestone JA, Derynck R

Tolerance induction and reversal of diabetes in mice transplanted with human embryonic stem cell-derived pancreatic endoderm.

Cell stem cell

Szot GL, Yadav M, Lang J, Kroon E, Kerr J, Kadoya K, Brandon EP, Baetge EE, Bour-Jordan H, Bluestone JA

Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy.

Blood

Van Gool F, Molofsky AB, Morar MM, Rosenzwajg M, Liang HE, Klatzmann D, Locksley RM, Bluestone JA

Regulatory T cells suppress muscle inflammation and injury in muscular dystrophy.

Science translational medicine

Villalta SA, Rosenthal W, Martinez L, Kaur A, Sparwasser T, Tidball JG, Margeta M, Spencer MJ, Bluestone JA

Aberrant innate immune activation following tissue injury impairs pancreatic regeneration.

PloS one

Folias AE, Penaranda C, Su AL, Bluestone JA, Hebrok M

Tyrosine 201 of the cytoplasmic tail of CTLA-4 critically affects T regulatory cell suppressive function.

European journal of immunology

Stumpf M, Zhou X, Chikuma S, Bluestone JA

Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis.

Nature medicine

Komatsu N, Okamoto K, Sawa S, Nakashima T, Oh-hora M, Kodama T, Tanaka S, Bluestone JA, Takayanagi H

Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response.

Immunity

Bailey-Bucktrout SL, Martinez-Llordella M, Zhou X, Anthony B, Rosenthal W, Luche H, Fehling HJ, Bluestone JA

Regulatory T-cell therapy in transplantation: moving to the clinic.

Cold Spring Harbor perspectives in medicine

Tang Q, Bluestone JA

Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial.

The lancet. Diabetes & endocrinology

Gitelman SE, Gottlieb PA, Rigby MR, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, Ding L, Bluestone JA, Ehlers MR

Peripherally induced tregs - role in immune homeostasis and autoimmunity.

Frontiers in immunology

Yadav M, Stephan S, Bluestone JA

CD28-inducible transcription factor DEC1 is required for efficient autoreactive CD4+ T cell response.

The Journal of experimental medicine

Martínez-Llordella M, Esensten JH, Bailey-Bucktrout SL, Lipsky RH, Marini A, Chen J, Mughal M, Mattson MP, Taub DD, Bluestone JA

Production of a-galactosylceramide by a prominent member of the human gut microbiota.

PLoS biology

Wieland Brown LC, Penaranda C, Kashyap PC, Williams BB, Clardy J, Kronenberg M, Sonnenburg JL, Comstock LE, Bluestone JA, Fischbach MA

microRNA-17-92 regulates IL-10 production by regulatory T cells and control of experimental autoimmune encephalomyelitis.

Journal of immunology (Baltimore, Md. : 1950)

de Kouchkovsky D, Esensten JH, Rosenthal WL, Morar MM, Bluestone JA, Jeker LT

Distinct genetic control of autoimmune neuropathy and diabetes in the non-obese diabetic background.

Journal of autoimmunity

Bour-Jordan H, Thompson HL, Giampaolo JR, Davini D, Rosenthal W, Bluestone JA

Inhibition of VEGFR-2 reverses type 1 diabetes in NOD mice by abrogating insulitis and restoring islet function.

Diabetes

Villalta SA, Lang J, Kubeck S, Kabre B, Szot GL, Calderon B, Wasserfall C, Atkinson MA, Brekken RA, Pullen N, Arch RH, Bluestone JA

Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.

Diabetes

Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA

The microRNA cluster miR-17~92 promotes TFH cell differentiation and represses subset-inappropriate gene expression.

Nature immunology

Baumjohann D, Kageyama R, Clingan JM, Morar MM, Patel S, de Kouchkovsky D, Bannard O, Bluestone JA, Matloubian M, Ansel KM, Jeker LT

MicroRNA regulation of T-cell differentiation and function.

Immunological reviews

Jeker LT, Bluestone JA

Cell-based therapeutics: the next pillar of medicine.

Science translational medicine

Fischbach MA, Bluestone JA, Lim WA

Regulatory T cells: recommendations to simplify the nomenclature.

Nature immunology

Abbas AK, Benoist C, Bluestone JA, Campbell DJ, Ghosh S, Hori S, Jiang S, Kuchroo VK, Mathis D, Roncarolo MG, Rudensky A, Sakaguchi S, Shevach EM, Vignali DA, Ziegler SF

Type 1 diabetes: translating mechanistic observations into effective clinical outcomes.

Nature reviews. Immunology

Herold KC, Vignali DA, Cooke A, Bluestone JA

Cutting Edge: a novel, human-specific interacting protein couples FOXP3 to a chromatin-remodeling complex that contains KAP1/TRIM28.

Journal of immunology (Baltimore, Md. : 1950)

Huang C, Martin S, Pfleger C, Du J, Buckner JH, Bluestone JA, Riley JL, Ziegler SF

Immune therapy and ß-cell death in type 1 diabetes.

Diabetes

Lebastchi J, Deng S, Lebastchi AH, Beshar I, Gitelman S, Willi S, Gottlieb P, Akirav EM, Bluestone JA, Herold KC

The B7-independent isoform of CTLA-4 functions to regulate autoimmune diabetes.

Journal of immunology (Baltimore, Md. : 1950)

Stumpf M, Zhou X, Bluestone JA

Current and future immunomodulation strategies to restore tolerance in autoimmune diseases.

Cold Spring Harbor perspectives in biology

Bluestone JA, Bour-Jordan H

Altered balance between effector T cells and FOXP3+ HELIOS+ regulatory T cells after thymoglobulin induction in kidney transplant recipients.

Transplant international : official journal of the European Society for Organ Transplantation

Tang Q, Leung J, Melli K, Lay K, Chuu EL, Liu W, Bluestone JA, Kang SM, Peddi VR, Vincenti F

Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo.

The Journal of experimental medicine

Yadav M, Louvet C, Davini D, Gardner JM, Martinez-Llordella M, Bailey-Bucktrout S, Anthony BA, Sverdrup FM, Head R, Kuster DJ, Ruminski P, Weiss D, Von Schack D, Bluestone JA

Single step isolation and activation of primary CD3+ T lymphocytes using alcohol-dispersed electrospun magnetic nanofibers.

Nano letters

Kim K, An HJ, Jun SH, Kim TJ, Lim SA, Park G, Na HB, Park YI, Hyeon T, Yee C, Bluestone JA, Kim J, Lee KM

IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cells.

Proceedings of the National Academy of Sciences of the United States of America

Penaranda C, Kuswanto W, Hofmann J, Kenefeck R, Narendran P, Walker LS, Bluestone JA, Abbas AK, Dooms H

Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs ß-cell function.

Diabetes

Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, Ahmann A, Rabinovitch A, Aggarwal S, Phippard D, Turka LA, Ehlers MR, Bianchine PJ, Boyle KD, Adah SA, Bluestone JA, Buckner JH, Greenbaum CJ

MicroRNA 10a marks regulatory T cells.

PloS one

Jeker LT, Zhou X, Gershberg K, de Kouchkovsky D, Morar MM, Stadthagen G, Lund AH, Bluestone JA

NK cells are not required for spontaneous autoimmune diabetes in NOD mice.

PloS one

Beilke JN, Meagher CT, Hosiawa K, Champsaur M, Bluestone JA, Lanier LL

A resource for the conditional ablation of microRNAs in the mouse.

Cell reports

Park CY, Jeker LT, Carver-Moore K, Oh A, Liu HJ, Cameron R, Richards H, Li Z, Adler D, Yoshinaga Y, Martinez M, Nefadov M, Abbas AK, Weiss A, Lanier LL, de Jong PJ, Bluestone JA, Srivastava D, McManus MT

Breakdown in peripheral tolerance in type 1 diabetes in mice and humans.

Cold Spring Harbor perspectives in medicine

Jeker LT, Bour-Jordan H, Bluestone JA

CD4(+)Foxp3(+) regulatory T cell therapy in transplantation.

Journal of molecular cell biology

Tang Q, Bluestone JA, Kang SM

The yin and yang of interleukin-2-mediated immunotherapy.

The New England journal of medicine

Bluestone JA

A mimic of viral double-stranded RNA triggers fulminant type 1 diabetes-like syndrome in regulatory T cell-deficient autoimmune diabetic mouse.

Journal of immunology (Baltimore, Md. : 1950)

Tada A, Shimada A, Yamada T, Oikawa Y, Yamada Y, Okubo Y, Irie J, Bluestone JA, Itoh H

Pillars article: CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994. 1: 405-413.

Journal of immunology (Baltimore, Md. : 1950)

Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA

Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation.

Nature immunology

Beyer M, Thabet Y, Müller RU, Sadlon T, Classen S, Lahl K, Basu S, Zhou X, Bailey-Bucktrout SL, Krebs W, Schönfeld EA, Böttcher J, Golovina T, Mayer CT, Hofmann A, Sommer D, Debey-Pascher S, Endl E, Limmer A, Hippen KL, Blazar BR, Balderas R, Quast T, Waha A, Mayer G, Famulok M, Knolle PA, Wickenhauser C, Kolanus W, Schermer B, Bluestone JA, Barry SC, Sparwasser T, Riley JL, Schultze JL

Type 1 diabetes immunotherapy: is the glass half empty or half full?

Science translational medicine

Herold KC, Bluestone JA

Control of TH17 cells occurs in the small intestine.

Nature

Esplugues E, Huber S, Gagliani N, Hauser AE, Town T, Wan YY, O'Connor W, Rongvaux A, Van Rooijen N, Haberman AM, Iwakura Y, Kuchroo VK, Kolls JK, Bluestone JA, Herold KC, Flavell RA

Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells.

Journal of immunology (Baltimore, Md. : 1950)

Penaranda C, Tang Q, Bluestone JA

Regulatory T cells: stability revisited.

Trends in immunology

Bailey-Bucktrout SL, Bluestone JA

Evidence that Cd101 is an autoimmune diabetes gene in nonobese diabetic mice.

Journal of immunology (Baltimore, Md. : 1950)

Rainbow DB, Moule C, Fraser HI, Clark J, Howlett SK, Burren O, Christensen M, Moody V, Steward CA, Mohammed JP, Fusakio ME, Masteller EL, Finger EB, Houchins JP, Naf D, Koentgen F, Ridgway WM, Todd JA, Bluestone JA, Peterson LB, Mattner J, Wicker LS

How does type 1 diabetes develop?: the notion of homicide or ß-cell suicide revisited.

Diabetes

Atkinson MA, Bluestone JA, Eisenbarth GS, Hebrok M, Herold KC, Accili D, Pietropaolo M, Arvan PR, Von Herrath M, Markel DS, Rhodes CJ

Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/?B7 family.

Immunological reviews

Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, Bluestone JA

Mechanisms of tolerance.

Immunological reviews

Bluestone JA

Requirements for prolongation of allograft survival with regulatory T cell infusion in lymphosufficient hosts.

The Journal of surgical research

Brennan TV, Tang Q, Liu FC, Hoang V, Bi M, Bluestone JA, Kang SM

Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes.

Journal of immunology (Baltimore, Md. : 1950)

McClymont SA, Putnam AL, Lee MR, Esensten JH, Liu W, Hulme MA, Hoffmüller U, Baron U, Olek S, Bluestone JA, Brusko TM

Cutting edge: vasostatin-1-derived peptide ChgA29-42 is an antigenic epitope of diabetogenic BDC2.5 T cells in nonobese diabetic mice.

Journal of immunology (Baltimore, Md. : 1950)

Nikoopour E, Sandrock C, Huszarik K, Krougly O, Lee-Chan E, Masteller EL, Bluestone JA, Singh B

Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade.

Transplantation

Posselt AM, Szot GL, Frassetto LA, Masharani U, Tavakol M, Amin R, McElroy J, Ramos MD, Kerlan RK, Fong L, Vincenti F, Bluestone JA, Stock PG

Expression of avß8 integrin on dendritic cells regulates Th17 cell development and experimental autoimmune encephalomyelitis in mice.

The Journal of clinical investigation

Melton AC, Bailey-Bucktrout SL, Travis MA, Fife BT, Bluestone JA, Sheppard D

The Immune Tolerance Network at 10 years: tolerance research at the bedside.

Nature reviews. Immunology

Bluestone JA, Auchincloss H, Nepom GT, Rotrosen D, St Clair EW, Turka LA

Clusterin synergizes with IL-2 for the expansion and IFN-? production of natural killer cells.

Journal of leukocyte biology

Sonn CH, Yu YB, Hong YJ, Shim YJ, Bluestone JA, Min BH, Lee KM

IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells.

The Journal of experimental medicine

Grinberg-Bleyer Y, Baeyens A, You S, Elhage R, Fourcade G, Gregoire S, Cagnard N, Carpentier W, Tang Q, Bluestone J, Chatenoud L, Klatzmann D, Salomon BL, Piaggio E

FK506 causes cellular and functional defects in human natural killer cells.

Journal of leukocyte biology

Kim TJ, Kim N, Kang HJ, Kim EO, Kim ST, Ahn HS, Bluestone JA, Lee KM

Human antigen-specific regulatory T cells generated by T cell receptor gene transfer.

PloS one

Brusko TM, Koya RC, Zhu S, Lee MR, Putnam AL, McClymont SA, Nishimura MI, Han S, Chang LJ, Atkinson MA, Ribas A, Bluestone JA

Small RNA regulators of T cell-mediated autoimmunity.

Journal of clinical immunology

Jeker LT, Bluestone JA

Ten years of the Immune Tolerance Network: an integrated clinical research organization.

Science translational medicine

Bluestone JA, Krensky AM, Turka LA, Rotrosen D, Matthews JB

Regulatory T cells directed to the site of the action.

Proceedings of the National Academy of Sciences of the United States of America

Brusko TM, Bluestone JA

Autoimmunity.

Current opinion in immunology

Bluestone JA, Kuchroo V

The functional plasticity of T cell subsets.

Nature reviews. Immunology

Bluestone JA, Mackay CR, O'Shea JJ, Stockinger B

How suppressor cells led to anergy, costimulation, and beyond.

Journal of immunology (Baltimore, Md. : 1950)

Bour-Jordan H, Bluestone JA

Regulatory T cells as therapeutic targets in rheumatoid arthritis.

Nature reviews. Rheumatology

Esensten JH, Wofsy D, Bluestone JA

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.

Nature immunology

Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, Azuma M, Krummel MF, Bluestone JA

Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo.

Nature immunology

Zhou X, Bailey-Bucktrout SL, Jeker LT, Penaranda C, Martínez-Llordella M, Ashby M, Nakayama M, Rosenthal W, Bluestone JA

Insulin receptor substrate-2 in beta-cells decreases diabetes in nonobese diabetic mice.

Endocrinology

Norquay LD, D'Aquino KE, Opare-Addo LM, Kuznetsova A, Haas M, Bluestone JA, White MF

Lethal effect of CD3-specific antibody in mice deficient in TGF-beta1 by uncontrolled flu-like syndrome.

Journal of immunology (Baltimore, Md. : 1950)

Perruche S, Zhang P, Maruyama T, Bluestone JA, Saas P, Chen W

T-bet-deficient NOD mice are protected from diabetes due to defects in both T cell and innate immune system function.

Journal of immunology (Baltimore, Md. : 1950)

Esensten JH, Lee MR, Glimcher LH, Bluestone JA

Anti-CTLA-4 treatment induces IL-10-producing ICOS+ regulatory T cells displaying IDO-dependent anti-inflammatory properties in a mouse model of colitis.

Gut

Coquerelle C, Oldenhove G, Acolty V, Denoeud J, Vansanten G, Verdebout JM, Mellor A, Bluestone JA, Moser M

Plasticity of CD4(+) FoxP3(+) T cells.

Current opinion in immunology

Zhou X, Bailey-Bucktrout S, Jeker LT, Bluestone JA

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.

Clinical immunology (Orlando, Fla.)

Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, Sayre P, Bianchine P, Wong E, Seyfert-Margolis V, Bourcier K, Bluestone JA

A novel myelin P0-specific T cell receptor transgenic mouse develops a fulminant autoimmune peripheral neuropathy.

The Journal of experimental medicine

Louvet C, Kabre BG, Davini DW, Martinier N, Su MA, DeVoss JJ, Rosenthal WL, Anderson MS, Bour-Jordan H, Bluestone JA

The role of X-linked FOXP3 in the autoimmune susceptibility of Turner Syndrome patients.

Clinical immunology (Orlando, Fla.)

Su MA, Stenerson M, Liu W, Putnam A, Conte F, Bluestone JA, Anderson MS

Expansion of human regulatory T-cells from patients with type 1 diabetes.

Diabetes

Putnam AL, Brusko TM, Lee MR, Liu W, Szot GL, Ghosh T, Atkinson MA, Bluestone JA

Immunoregulatory pathways controlling progression of autoimmunity in NOD mice.

Annals of the New York Academy of Sciences

You S, Alyanakian MA, Segovia B, Damotte D, Bluestone J, Bach JF, Chatenoud L

Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice.

Proceedings of the National Academy of Sciences of the United States of America

Louvet C, Szot GL, Lang J, Lee MR, Martinier N, Bollag G, Zhu S, Weiss A, Bluestone JA

The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Bluestone JA, Liu W, Yabu JM, Laszik ZG, Putnam A, Belingheri M, Gross DM, Townsend RM, Vincenti F

Innate immunity and intestinal microbiota in the development of Type 1 diabetes.

Nature

Wen L, Ley RE, Volchkov PY, Stranges PB, Avanesyan L, Stonebraker AC, Hu C, Wong FS, Szot GL, Bluestone JA, Gordon JI, Chervonsky AV

Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity.

The Journal of experimental medicine

Zhou X, Jeker LT, Fife BT, Zhu S, Anderson MS, McManus MT, Bluestone JA

T regulatory cells in autoimmune diabetes: past challenges, future prospects.

Journal of clinical immunology

Bluestone JA, Tang Q, Sedwick CE

Targeting CD22 reprograms B-cells and reverses autoimmune diabetes.

Diabetes

Fiorina P, Vergani A, Dada S, Jurewicz M, Wong M, Law K, Wu E, Tian Z, Abdi R, Guleria I, Rodig S, Dunussi-Joannopoulos K, Bluestone J, Sayegh MH

Spontaneous development of a pancreatic exocrine disease in CD28-deficient NOD mice.

Journal of immunology (Baltimore, Md. : 1950)

Meagher C, Tang Q, Fife BT, Bour-Jordan H, Wu J, Pardoux C, Bi M, Melli K, Bluestone JA

Human regulatory T cells: role in autoimmune disease and therapeutic opportunities.

Immunological reviews

Brusko TM, Putnam AL, Bluestone JA

Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction.

Immunity

Tang Q, Adams JY, Penaranda C, Melli K, Piaggio E, Sgouroudis E, Piccirillo CA, Salomon BL, Bluestone JA

Safer, longer-lasting regulatory T cells with beta-catenin.

Nature medicine

Bluestone JA, Hebrok M

Regulated beta-cell regeneration in the adult mouse pancreas.

Diabetes

Cano DA, Rulifson IC, Heiser PW, Swigart LB, Pelengaris S, German M, Evan GI, Bluestone JA, Hebrok M

B cell depletion: a novel therapy for autoimmune diabetes?

The Journal of clinical investigation

Bour-Jordan H, Bluestone JA

Transplantation of pancreatic islets into the kidney capsule of diabetic mice.

Journal of visualized experiments : JoVE

Szot GL, Koudria P, Bluestone JA

Murine pancreatic islet isolation.

Journal of visualized experiments : JoVE

Szot GL, Koudria P, Bluestone JA

Loss of integrin alpha(v)beta8 on dendritic cells causes autoimmunity and colitis in mice.

Nature

Travis MA, Reizis B, Melton AC, Masteller E, Tang Q, Proctor JM, Wang Y, Bernstein X, Huang X, Reichardt LF, Bluestone JA, Sheppard D

Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells.

Endocrinology

Sherry NA, Chen W, Kushner JA, Glandt M, Tang Q, Tsai S, Santamaria P, Bluestone JA, Brillantes AM, Herold KC

What does the future hold for cell-based tolerogenic therapy?

Nature reviews. Immunology

Bluestone JA, Thomson AW, Shevach EM, Weiner HL

CD3-specific antibodies: a portal to the treatment of autoimmunity.

Nature reviews. Immunology

Chatenoud L, Bluestone JA

Constitutive expression of B7-1 on B cells uncovers autoimmunity toward the B cell compartment in the nonobese diabetic mouse.

Journal of immunology (Baltimore, Md. : 1950)

Bour-Jordan H, Salomon BL, Thompson HL, Santos R, Abbas AK, Bluestone JA

Mechanisms of PDL1-mediated regulation of autoimmune diabetes.

Clinical immunology (Orlando, Fla.)

Guleria I, Gubbels Bupp M, Dada S, Fife B, Tang Q, Ansari MJ, Trikudanathan S, Vadivel N, Fiorina P, Yagita H, Azuma M, Atkinson M, Bluestone JA, Sayegh MH

Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment.

Proceedings of the National Academy of Sciences of the United States of America

You S, Leforban B, Garcia C, Bach JF, Bluestone JA, Chatenoud L

New reagents on the horizon for immune tolerance.

Annual review of medicine

St Clair EW, Turka LA, Saxon A, Matthews JB, Sayegh MH, Eisenbarth GS, Bluestone J

Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway.

The Journal of experimental medicine

Fife BT, Guleria I, Gubbels Bupp M, Eagar TN, Tang Q, Bour-Jordan H, Yagita H, Azuma M, Sayegh MH, Bluestone JA

International trial of the Edmonton protocol for islet transplantation.

The New England journal of medicine

Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP, Secchi A, Brendel MD, Berney T, Brennan DC, Cagliero E, Alejandro R, Ryan EA, DiMercurio B, Morel P, Polonsky KS, Reems JA, Bretzel RG, Bertuzzi F, Froud T, Kandaswamy R, Sutherland DE, Eisenbarth G, Segal M, Preiksaitis J, Korbutt GS, Barton FB, Viviano L, Seyfert-Margolis V, Bluestone J, Lakey JR

Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study.

Diabetes

Seyfert-Margolis V, Gisler TD, Asare AL, Wang RS, Dosch HM, Brooks-Worrell B, Eisenbarth GS, Palmer JP, Greenbaum CJ, Gitelman SE, Nepom GT, Bluestone JA, Herold KC

Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist.

The Journal of clinical investigation

Fife BT, Griffin MD, Abbas AK, Locksley RM, Bluestone JA

Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells.

Journal of immunology (Baltimore, Md. : 1950)

Scalapino KJ, Tang Q, Bluestone JA, Bonyhadi ML, Daikh DI

CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells.

The Journal of experimental medicine

Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St Groth B, Clayberger C, Soper DM, Ziegler SF, Bluestone JA

Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs.

The Journal of clinical investigation

Bresson D, Togher L, Rodrigo E, Chen Y, Bluestone JA, Herold KC, von Herrath M

CTLA4Ig: bridging the basic immunology with clinical application.

Immunity

Bluestone JA, St Clair EW, Turka LA

Antigen-specific regulatory T cells--ex vivo expansion and therapeutic potential.

Seminars in immunology

Masteller EL, Tang Q, Bluestone JA

Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice.

Nature immunology

Tang Q, Adams JY, Tooley AJ, Bi M, Fife BT, Serra P, Santamaria P, Locksley RM, Krummel MF, Bluestone JA

Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen.

The Journal of experimental medicine

Knoechel B, Lohr J, Kahn E, Bluestone JA, Abbas AK

Distinct effector mechanisms in the development of autoimmune neuropathy versus diabetes in nonobese diabetic mice.

Journal of immunology (Baltimore, Md. : 1950)

Bour-Jordan H, Thompson HL, Bluestone JA

How do CD4+CD25+ regulatory T cells control autoimmunity?

Current opinion in immunology

Bluestone JA, Tang Q

A peptide of glutamic acid decarboxylase 65 can recruit and expand a diabetogenic T cell clone, BDC2.5, in the pancreas.

Journal of immunology (Baltimore, Md. : 1950)

Dai YD, Jensen KP, Lehuen A, Masteller EL, Bluestone JA, Wilson DB, Sercarz EE

TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs.

The Journal of clinical investigation

Bisikirska B, Colgan J, Luban J, Bluestone JA, Herold KC

Achieving antigen-specific tolerance in diabetes: regulating specifically.

International reviews of immunology

Chen W, Bluestone JA, Herold KC

Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice.

Journal of immunology (Baltimore, Md. : 1950)

Masteller EL, Warner MR, Tang Q, Tarbell KV, McDevitt H, Bluestone JA

A comprehensive review of interventions in the NOD mouse and implications for translation.

Immunity

Shoda LK, Young DL, Ramanujan S, Whiting CC, Atkinson MA, Bluestone JA, Eisenbarth GS, Mathis D, Rossini AA, Campbell SE, Kahn R, Kreuwel HT

B7-independent inhibition of T cells by CTLA-4.

Journal of immunology (Baltimore, Md. : 1950)

Chikuma S, Abbas AK, Bluestone JA

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.

Diabetes

Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, Bluestone JA

An important role of CD80/CD86-CTLA-4 signaling during photocarcinogenesis in mice.

Journal of immunology (Baltimore, Md. : 1950)

Loser K, Scherer A, Krummen MB, Varga G, Higuchi T, Schwarz T, Sharpe AH, Grabbe S, Bluestone JA, Beissert S

Distinct roles of dendritic cells and B cells in Va14Ja18 natural T cell activation in vivo.

Journal of immunology (Baltimore, Md. : 1950)

Bezbradica JS, Stanic AK, Matsuki N, Bour-Jordan H, Bluestone JA, Thomas JW, Unutmaz D, Van Kaer L, Joyce S

Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis.

Journal of immunology (Baltimore, Md. : 1950)

Kohm AP, Williams JS, Bickford AL, McMahon JS, Chatenoud L, Bach JF, Bluestone JA, Miller SD

Regulatory T-cell therapy: is it ready for the clinic?

Nature reviews. Immunology

Bluestone JA

CTLA-4Ig is finally making it: a personal perspective.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Bluestone JA

Differential roles of costimulatory signaling pathways in type 1 diabetes mellitus.

The review of diabetic studies : RDS

Boehm BO, Bluestone JA

The NOD mouse: a model of immune dysregulation.

Annual review of immunology

Anderson MS, Bluestone JA

Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function.

European journal of immunology

Tang Q, Boden EK, Henriksen KJ, Bour-Jordan H, Bi M, Bluestone JA

Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells.

The Journal of clinical investigation

Bour-Jordan H, Salomon BL, Thompson HL, Szot GL, Bernhard MR, Bluestone JA

Peptide specific amelioration of T cell mediated pathogenesis in murine type 1 diabetes.

Clinical immunology (Orlando, Fla.)

Judkowski V, Rodriguez E, Pinilla C, Masteller E, Bluestone JA, Sarvetnick N, Wilson DB

Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells.

Proceedings of the National Academy of Sciences of the United States of America

Bluestone JA, Tang Q

CTLA-4 regulates expansion and differentiation of Th1 cells following induction of peripheral T cell tolerance.

Journal of immunology (Baltimore, Md. : 1950)

Eagar TN, Turley DM, Padilla J, Karandikar NJ, Tan L, Bluestone JA, Miller SD

In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes.

The Journal of experimental medicine

Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, Ye J, Masteller EL, McDevitt H, Bonyhadi M, Bluestone JA

NKG2D blockade prevents autoimmune diabetes in NOD mice.

Immunity

Ogasawara K, Hamerman JA, Ehrlich LR, Bour-Jordan H, Santamaria P, Bluestone JA, Lanier LL

Notch signaling in lymphocyte development and function.

Current opinion in immunology

Robey EA, Bluestone JA

Notch 1 signaling regulates peripheral T cell activation.

Immunity

Eagar TN, Tang Q, Wolfe M, He Y, Pear WS, Bluestone JA

Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Hering BJ, Kandaswamy R, Harmon JV, Ansite JD, Clemmings SM, Sakai T, Paraskevas S, Eckman PM, Sageshima J, Nakano M, Sawada T, Matsumoto I, Zhang HJ, Sutherland DE, Bluestone JA

Importance of IL-10 for CTLA-4-mediated inhibition of tumor-eradicating immunity.

Journal of immunology (Baltimore, Md. : 1950)

Jovasevic VM, Gorelik L, Bluestone JA, Mokyr MB

Insulin secretion in type 1 diabetes.

Diabetes

Steele C, Hagopian WA, Gitelman S, Masharani U, Cavaghan M, Rother KI, Donaldson D, Harlan DM, Bluestone J, Herold KC

Beta-cell replacement for type I diabetes.

Annual review of medicine

Stock PG, Bluestone JA

Peptide-MHC class II dimers as therapeutics to modulate antigen-specific T cell responses in autoimmune diabetes.

Journal of immunology (Baltimore, Md. : 1950)

Masteller EL, Warner MR, Ferlin W, Judkowski V, Wilson D, Glaichenhaus N, Bluestone JA

Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells.

Journal of immunology (Baltimore, Md. : 1950)

Tang Q, Henriksen KJ, Boden EK, Tooley AJ, Ye J, Subudhi SK, Zheng XX, Strom TB, Bluestone JA

TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes.

Nature medicine

Belghith M, Bluestone JA, Barriot S, Mégret J, Bach JF, Chatenoud L

Clinical trials of transplant tolerance: slow but steady progress.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Matthews JB, Ramos E, Bluestone JA

Altered cutaneous immune parameters in transgenic mice overexpressing viral IL-10 in the epidermis.

The Journal of clinical investigation

Ding W, Beissert S, Deng L, Miranda E, Cassetty C, Seiffert K, Campton KL, Yan Z, Murphy GF, Bluestone JA, Granstein RD

Natural versus adaptive regulatory T cells.

Nature reviews. Immunology

Bluestone JA, Abbas AK

Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).

The Journal of clinical investigation

Herold KC, Burton JB, Francois F, Poumian-Ruiz E, Glandt M, Bluestone JA

CD28/B7 regulation of anti-CD3-mediated immunosuppression in vivo.

Journal of immunology (Baltimore, Md. : 1950)

Tang Q, Smith JA, Szot GL, Zhou P, Alegre ML, Henriksen KJ, Thompson CB, Bluestone JA

Directed evolution of a single-chain class II MHC product by yeast display.

Protein engineering

Starwalt SE, Masteller EL, Bluestone JA, Kranz DM

CTLA-4 regulates the requirement for cytokine-induced signals in T(H)2 lineage commitment.

Nature immunology

Bour-Jordan H, Grogan JL, Tang Q, Auger JA, Locksley RM, Bluestone JA

Negative regulation of T cell receptor-lipid raft interaction by cytotoxic T lymphocyte-associated antigen 4.

The Journal of experimental medicine

Chikuma S, Imboden JB, Bluestone JA

CTLA-4 and tolerance: the biochemical point of view.

Immunologic research

Chikuma S, Bluestone JA

Impairment of NK cell function by NKG2D modulation in NOD mice.

Immunity

Ogasawara K, Hamerman JA, Hsin H, Chikuma S, Bour-Jordan H, Chen T, Pertel T, Carnaud C, Bluestone JA, Lanier LL

The role of CD28 and CTLA4 in the function and homeostasis of CD4+CD25+ regulatory T cells.

Novartis Foundation symposium

Boden E, Tang Q, Bour-Jordan H, Bluestone JA

When ligand becomes receptor--tolerance via B7 signaling on DCs.

Nature immunology

Finger EB, Bluestone JA

Immunotherapy of insulin-dependent diabetes mellitus.

Current opinion in immunology

Masteller EL, Bluestone JA

Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial.

The Journal of rheumatology

Utset TO, Auger JA, Peace D, Zivin RA, Xu D, Jolliffe L, Alegre ML, Bluestone JA, Clark MR

Cutting edge: targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells.

Journal of immunology (Baltimore, Md. : 1950)

Hwang KW, Sweatt WB, Brown IE, Blank C, Gajewski TF, Bluestone JA, Alegre ML

CTLA-4: acting at the synapse.

Molecular interventions

Chikuma S, Bluestone JA

Inability to induce tolerance through direct antigen presentation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Rulifson IC, Szot GL, Palmer E, Bluestone JA

The immune tolerance network: a new paradigm for developing tolerance-inducing therapies.

The Journal of allergy and clinical immunology

Rotrosen D, Matthews JB, Bluestone JA

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.

The New England journal of medicine

Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA

The Src family kinase Fyn mediates signals induced by TCR antagonists.

Journal of immunology (Baltimore, Md. : 1950)

Tang Q, Subudhi SK, Henriksen KJ, Long CG, Vives F, Bluestone JA

The role of CTLA-4 in induction and maintenance of peripheral T cell tolerance.

European journal of immunology

Eagar TN, Karandikar NJ, Bluestone JA, Miller SD